Table 2.

Demographic, serological and clinical findings in patients with MN and viral infection

													Treatment		Last follow-up
Case no	MN age	Sex	Ethnicity	Virology	PLA2R biopsy	THSD7A	Lupus serology	Viral load	CD4 cells/uL	GFR	uPCR	anti-PLA2R serum	MN	Anti-viral	FU months	GFR	uPCR	anti-PLA2R serum	Complications
1	23	F	Asian	HBV	Neg	No tissue	Neg	HBV 83 210 copies/mL	NA	>60	590	NA	Tacrolimus	Tenofovir	24	>60	0	NA	Nephrotic in pregnancy
2	43	F	Asian	HBV	Pos	NA	Neg	HBV 1190 iu/mL	NA	>90	1030	75	Tacrolimus	Entecavir	48	48	229	2	Crescentic transformation, treated with RTX and CyP
3	39	M	Asian	HBV	Pos	NA	Neg	HBV <100 copies/mL	NA	55	170	NA	Tacrolimus	Lamivudine	48	50	0	NA	None
4	65	F	Caucasian	HBV	Pos	NA	Neg	HBV <20 copies/mL	NA	89	1337	99	Supportive	None	7	81	542	28	None
5	39	F	Asian	HBV	Neg	Pos	Neg	HBV<20 copies/mL	NA	>90	675	Neg	Supportive	None	32	>90	240	NA	None
6	26	M	Asian	HBV	Pos	NA	Neg	HBV <20 copies/mL	NA	>90	896	30	Tacrolimus	Tenofovir	15	>90	57	9	None
7	50	M	Caucasian	HCV	Pos	NA	Neg	HCV undetectable	NA	>60	1253	NA	Tacrolimus	Interferon and ribavirin	132	HD	HD	3	Relapse, treated with CyP and steroids, ESRD
8	68	M	Asian	HCV	Pos	NA	Neg	HCV undetectable	NA	>90	801	93	Tacrolimus	Interferon	46	80	425	2	Guillain-Barre pre-MN, flare MN treated with RTX
9	41	M	Caucasian	HCV	Pos	NA	ANA+ 1:160	HCV undetectable	NA	>90	1800	110	Tacrolimus	None	39	>90	570	3.5	Alc liver disease, non- compliant, changed to RTX
10	33	F	Asian	HCV	Neg	Neg	Neg	HCV undetectable	NA	>90	1.989	Neg	Tacrolimus	None	15	>90	51	NA	None
11	31	M	Afro-Caribbean	HIV	Neg	NA	Neg	HIV 1489 copies/mL	800	67	65	NA	Supportive	None	64	75	53	NA	None
12	46	M	Caucasian	HIV	Neg	Pos	Neg	HIV 81 copies/mL	630	>90	854	Neg	Tacrolimus	Atazanavir, emtricitabine, ritonavir and tenofovir	64	47	47	NA	None
13	26	M	Afro-Caribbean	HIV	Neg	Neg	Neg	HIV <20 copies/mL	477	>90	77	NA	Supportive	Abacavir, darunavir, lamividine and ritonavir	16	>90	50	NA	None
14	47	F	Afro-Caribbean	HIV	Pos	NA	Neg	HIV <20 copies/mL	558	>90	207	NA	Supportive	Abacavir, lamivudine and rilpivirine	42	>90	220	NA	None
15	44	F	Afro-Caribbean	HIV	Neg	Pos	Neg	HIV <20 copies/mL	600	16	548	NA	Supportive	Abacavie, darunavir, lamivudine and ritonavir	27	HD	HD	NA	ESRD
16	37	F	Afro-Caribbean	HIV	Pos	NA	Neg	HIV <20 copies/mL	480	82	22	22	RTX	Abacavir, efavirenz and lamivudine	6	82	22	NA	Relapse at 5 years—retreated with RTX
17	25	F	Afro-Caribbean	HIV HBV	Neg	Neg	Neg	HBV 102 copies/mL HIV <20 copies/mL	NA	>60	286	NA	Supportive	Abacavir, entacavir, lamivudine, lopinavir and ritonavir	6	>60	150	NA	None
18	74	M	Afro-Caribbean	HIV HBV	Pos	NA	Neg	HBV undetectable HIV 21 copies/mL	505	61	2.406	67	Tacrolimus	Efavirenz, emtricitabine and tenofovir	6	61	626	34	Prostate cancer
19	73	M	Caucasian	HIV HCV	Neg	Neg	Neg	HCV undetectable HIV <20 copies/mL	571	44	133	Neg	Supportive	Emtricitabine, rilpivirine and tenofovir	10	57	52	NA	None

Lupus serology: antinuclear antibody, double-stranded DNA and endonuclear antibody; GFR: mL/min/1.73 m^2; UPCR: mg/mmol; anti-PLA2R antibodies: IU/mL; FU: follow-up; HD: haemodialysis; ESRD: end-stage renal disease; Pos: positive; Neg: negative; NA: not available.